✦ LIBER ✦

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer

✍ Scribed by Pui San Tan,Benjamin Haaland,Alberto J. Montero…

Book ID: 121481943
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 237 KB
Volume: 138
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2495-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of combination anastr

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

✍ Robert W. Carlson, Anne O’Neill, Tatiana Vidaurre, Henry L. Gomez, Sunil S. Badv 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 275 KB

A randomized, double-blind, controlled s

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

✍ Iwata, Hiroji; Masuda, Norikazu; Ohno, Shinji; Rai, Yoshiaki; Sato, Yasuyuki; Oh 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 315 KB

Pharmacokinetic Profile of the Fulvestra

Pharmacokinetic Profile of the Fulvestrant Loading Dose Regimen in Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer

✍ Peter McCormack; Francisco Sapunar 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 266 KB

Anastrozole is superior to tamoxifen as

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

✍ Jacques Bonneterre; Aman Buzdar; Jean-Marc A. Nabholtz; John F. R. Robertson; Be 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 2 views

5072 Independent central review of clini

5072 Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer

✍ J.P.O. Lindemann; J.F.R. Robertson; M.J. Ellis; Y. Menu; E.J. Macpherson; D.D.C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Quality-adjusted survival analysis of fi

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib

✍ Sherrill, Beth; Sherif, Bintu; Amonkar, Mayur M.; Maltzman, Julie; O’Rourke, Lis 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 497 KB